



## **Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025**

July 24, 2025 at 7:30 AM EDT

LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025.

Management will host a conference call and webcast at 8:30am EDT/13:30pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using [this link](#) to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the [events section](#) of Autolus' website.

### **About Autolus Therapeutics plc**

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL<sup>®</sup>, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit [www.autolus.com](http://www.autolus.com).

### **Contact:**

Amanda Cray  
+1 617-967-0207  
[a.cray@autolus.com](mailto:a.cray@autolus.com)